LIVIVO - Search results -

Search results

Result 1 - 10 of total 121

Search options

Book ; Thesis: Assoziation des Stromal-derived-Factor-1alpha 3'A Genotyps mit vaskulären Komplikationen bei Patienten mit Diabetes mellitus Typ 2 und Diabetischem Fußsyndrom

Battista, Marco Johannes

2008

Author's details	vorgelegt von Marco Johannes Battista
Language	German
Size	40 Bl. : Ill., graph. Darst.
Publishing country	Germany
Document type	Book ; Thesis
Thesis / German Habilitation thesis	Heidelberg, Univ., Diss., 2008
HBZ-ID	HT015836761
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2009 E 344	order for loan	Magazin

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions.

Alexa, Matthias / Hasenburg, Annette / Battista, Marco Johannes

Cancers

2021 Volume 13, Issue 6

Abstract: Adjuvant treatment decisions for endometrial cancer (EC) are based on stage, the histological grade of differentiation, histological subtype, and few histopathological markers. The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) ... ...

Abstract	Adjuvant treatment decisions for endometrial cancer (EC) are based on stage, the histological grade of differentiation, histological subtype, and few histopathological markers. The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) identified four risk groups of EC patients using a combination of immunohistochemistry and mutation analysis: Polymerase Epsilon exonuclease domain mutated (POLE EDM), mismatch repair deficient (MMRd), p53 wild-type/copy-number-low (p53 wt), and p53-mutated/copy-number-high (p53 abn). Patients allocated to the POLE or abnormal p53 expression subtype are faced with a significantly altered outcome possibly requiring a modified adjuvant treatment decision. Within this review, we summarize the development of ProMisE, characterize the four molecular subtypes, and finally discuss its value in terms of a patient-tailored therapy in order to prevent significant under or overtreatment.
Language	English
Publishing date	2021-03-23
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers13061478
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Metronomic Chemotherapy for Metastatic Breast Cancer.

Krajnak, Slavomir / Battista, Marco J / Hasenburg, Annette / Schmidt, Marcus

Oncology research and treatment

2021 Volume 45, Issue 1-2, Page(s) 12–17

Abstract: Background: As disease control and quality of life play a leading role in metastatic breast cancer (MBC), metronomic chemotherapy (MCT) is gaining popularity alongside conventional chemotherapy (CCT) and targeted therapies.: Summary: MCT, defined as ... ...

Abstract	Background: As disease control and quality of life play a leading role in metastatic breast cancer (MBC), metronomic chemotherapy (MCT) is gaining popularity alongside conventional chemotherapy (CCT) and targeted therapies. Summary: MCT, defined as continuous administration of low-dose chemotherapeutic agents, is accepted as a therapy that exerts its effects via immunomodulation, anti-angiogenesis and direct cytotoxic effects. Oral administration of MCT is safe, easy to handle, and allows for flexible drug dosing. Dose accumulations associated with non-tolerable side effects are rare, so the medication can be administered for longer periods of time. Patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic disease resistant to endocrine-based therapy and not requiring rapid tumor response are generally suitable for MCT. However, MCT may also be promising in patients with triple-negative and HER2-positive tumors without aggressive disease who prefer a lower toxicity profile compared to CCT. The most commonly used agents are cyclophosphamide (CTX), methotrexate (MTX), capecitabine (CAPE), and vinorelbine (VRL), whereby a combination of agents is frequently applied. Key Messages: Based on the growing body of evidence, MCT can be considered as a suitable treatment option in selected MBC patients. Nevertheless, there is an urgent need for randomized controlled trials comparing MCT with CCT, but also with best supportive care. Due to the multimodal mechanisms of action, the combination with targeted and immunological therapies may represent a new promising approach for the treatment of MBC.
MeSH term(s)	Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; Breast Neoplasms/drug therapy ; Capecitabine/therapeutic use ; Cyclophosphamide/therapeutic use ; Female ; Humans ; Quality of Life ; Receptor, ErbB-2
Chemical Substances	Antineoplastic Agents ; Capecitabine (6804DJ8Z9U) ; Cyclophosphamide (8N3DW7272P) ; Receptor, ErbB-2 (EC 2.7.10.1)
Language	English
Publishing date	2021-11-18
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	2760274-6
ISSN	2296-5262 ; 2296-5270
ISSN (online)	2296-5262
ISSN	2296-5270
DOI	10.1159/000520236
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1414: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature.

Linz, Valerie Catherine / Löwe, Amelie / van der Ven, Josche / Hasenburg, Annette / Battista, Marco Johannes

Frontiers in oncology

2022 Volume 12, Page(s) 951292

Abstract: Objective: Serous tubal intraepithelial carcinoma (STIC) is a precursor lesion of pelvic high-grade serous carcinoma (HGSC). Information on treatment and outcome of isolated STIC is rare. Therefore, we reviewed systematically the published literature to ...

Abstract	Objective: Serous tubal intraepithelial carcinoma (STIC) is a precursor lesion of pelvic high-grade serous carcinoma (HGSC). Information on treatment and outcome of isolated STIC is rare. Therefore, we reviewed systematically the published literature to determine the incidence of subsequent HGSC in the high- and low-risk population and to summarize the current diagnostic and therapeutic options. Methods: A systematic review of the literature was conducted in MEDLINE-Ovid, Cochrane Library and Web of Science of articles published from February 2006 to July 2021. Patients with an isolated STIC diagnosis and clinical follow-up were included. Study exclusion criteria for review were the presence of synchronous gynaecological cancer and/or concurrent non-gynaecological malignancies. Results: 3031 abstracts were screened. 112 isolated STIC patients out of 21 publications were included in our analysis with a pooled median follow-up of 36 (interquartile range (IQR): 25.3-84) months. 71.4% of the patients had peritoneal washings (negative: 62.5%, positive: 8%, atypic cells: 0.9%). Surgical staging was performed in 28.6% of all STICs and did not show any malignancies. 14 out of 112 (12.5%) patients received adjuvant chemotherapy with Carboplatin and Paclitaxel. Eight (7.1%) patients developed a recurrence 42.5 (IQR: 33-72) months after isolated STIC diagnosis. Cumulative incidence of HGSC after five (ten) years was 10.5% (21.6%). Recurrence occurred only in Conclusion: The rate of HGSC after an isolated STIC diagnosis was 7.1% with a cumulative incidence of 10.5% (21.6%) after five (ten) years. HGSC was only observed in Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42021278340.
Language	English
Publishing date	2022-08-31
Publishing country	Switzerland
Document type	Systematic Review
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2022.951292
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Immunohistochemical markers of prognosis in adult granulosa cell tumors of the ovary - a review.

Jung, Dennis / Almstedt, Katrin / Battista, Marco J / Seeger, Alexander / Jäkel, Jörg / Brenner, Walburgis / Hasenburg, Annette

Journal of ovarian research

2023 Volume 16, Issue 1, Page(s) 50

Abstract: Background: Granulosa cell tumors (GCT) are rare malignant ovarian tumors. The two subtypes, adult and juvenile granulosa cell tumors, differ in clinical and molecular characteristics. GCT are low-malignant tumors and are generally associated with ... ...

Abstract	Background: Granulosa cell tumors (GCT) are rare malignant ovarian tumors. The two subtypes, adult and juvenile granulosa cell tumors, differ in clinical and molecular characteristics. GCT are low-malignant tumors and are generally associated with favorable prognosis. However, relapses are common even years and decades after diagnosis. Prognostic and predictive factors are difficult to assess in this rare tumor entity. The purpose of this review is to provide a comprehensive overview of the current state of knowledge on prognostic markers of GCT to identify patients with a high risk of recurrence. Methods: Systematic research for adult ovarian granulosa cell tumors and prognosis revealed n = 409 English full text results from 1965 to 2021. Of these articles, n = 35 were considered for this review after title and abstract screening and topic-specific matching. A specific search for pathologic markers with prognostic relevance for GCT identified n = 19 articles that were added to this review. Results: FOXL2 mutation and FOXL2 mRNA were inverse and immunohistochemical (IHC) expression of CD56, GATA-4 and SMAD3 was associated with reduced prognosis. IHC analysis of estrogen receptor, Anti-Mullerian hormone (AMH) and inhibin was not associated with prognosis for GCT. Analyses of mitotic rate, Ki-67, p53, β-catenin and HER2 revealed inconsistent results.
MeSH term(s)	Female ; Humans ; Adult ; Granulosa Cell Tumor ; Prognosis ; Ovarian Neoplasms ; Pelvis
Language	English
Publishing date	2023-03-03
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2455679-8
ISSN	1757-2215 ; 1757-2215
ISSN (online)	1757-2215
ISSN	1757-2215
DOI	10.1186/s13048-023-01125-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Safety of misoprostol for near-term and term induction in small-for-gestational-age pregnancies compared to dinoprostone and primary cesarean section: results of a retrospective cohort study.

Steetskamp, Joscha / Bachmann, Elisabeth / Hasenburg, Annette / Battista, Marco Johannes

Archives of gynecology and obstetrics

2020 Volume 302, Issue 6, Page(s) 1369–1374

Abstract: Objectives: Small-for-gestational-age (SGA) pregnancy is a condition often leading to labor induction due to concerns about the possibility of an increased risk for fetal morbidity and mortality. In this retrospective cohort study, we try to evaluate ... ...

Abstract	Objectives: Small-for-gestational-age (SGA) pregnancy is a condition often leading to labor induction due to concerns about the possibility of an increased risk for fetal morbidity and mortality. In this retrospective cohort study, we try to evaluate the safety of oral misoprostol for labor induction in near-term and term pregnancies in SGA fetuses compared to dinoprostone as well as to planned primary cesarean section. Materials and methods: Retrospective analysis of labor indution and primary cesarean section in SGA pregnancies 37 weeks and beyond in a tertiary care centre. In total, 284 consecutive patients with SGA fetuses were included. 80 recieved oral misoprostol, 85 dinoprostone as vaginal Gel and 119 were delivered by means of primary cesarean section. Primary endpoints were umbilical aterial pH and APGAR 5'. Secondary endpoints were APGAR 1' and 10', rates of relevant acidosis with a pH < 7.11 and depressed children, NICU admissions and vaginal operative deliveries as well as cesarean sections after labor induction. Results: No significant differences were found concerning the umbilical arterial pH. No significant differences were found concerning APGAR 5' after labor induction; however, APGAR 5' was significantly lower after primary cesarean section. Similar results were found concerning APGAR 1', 10-min APGAR values were not significantly different. Rates of relevant acidosis and depressed children did not differ; no significant differences were found concerning NICU admissions between all groups and vaginal operative deliveries and CS rates after labor induciton. Conclusion: Oral misoprosol is a safe method for labor induction in SGA near-term and term pregnancies and, concerning the neonatal outcome, comparable with other methods of labor induction or primary CS. Our study showed no adverse neonatal outcomes related to the use of oral misoprostol.
MeSH term(s)	Administration, Intravaginal ; Adult ; Cesarean Section/statistics & numerical data ; Child ; Cohort Studies ; Delivery, Obstetric ; Dinoprostone/administration & dosage ; Female ; Humans ; Infant, Small for Gestational Age ; Labor, Induced/methods ; Misoprostol/administration & dosage ; Oxytocics/administration & dosage ; Pregnancy ; Pregnancy Outcome ; Pregnancy Trimester, Third ; Retrospective Studies ; Treatment Outcome
Chemical Substances	Oxytocics ; Misoprostol (0E43V0BB57) ; Dinoprostone (K7Q1JQR04M)
Language	English
Publishing date	2020-08-05
Publishing country	Germany
Document type	Comparative Study ; Evaluation Study ; Journal Article
ZDB-ID	896455-5
ISSN	1432-0711 ; 0932-0067
ISSN (online)	1432-0711
ISSN	0932-0067
DOI	10.1007/s00404-020-05703-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Um I Zs.55: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Conference proceedings ; Online: Auswirkungen der sozialen Isolation bzw. der häuslichen Quarantäne während der SARS-CoV-2 Pandemie auf die Krankheitsbewältigung von Endometriose-Patientinnen

Schwab, R / Gillen, K / Domidian, J.-S / Krajnak, S / Battista, M.J / Hasenburg, A

Kongressabstracts zur Tagung 2020 der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG)

2020

Keywords	covid19
Publisher	© 2020. Thieme. All rights reserved.
Publishing country	de
Document type	Conference proceedings ; Online
DOI	10.1055/s-0040-1718108
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Fulvestrant for the treatment of endometrial cancer.

Battista, Marco Johannes / Schmidt, Marcus

Expert opinion on investigational drugs

2016 Volume 25, Issue 4, Page(s) 475–483

Abstract: Introduction: About one third of patients with endometrial cancer (EC) relapse and face a limited prognosis, if surgery or radiotherapy are not feasible. The remaining therapeutic options are chemotherapy and endocrine therapy.: Areas covered: This ... ...

Abstract	Introduction: About one third of patients with endometrial cancer (EC) relapse and face a limited prognosis, if surgery or radiotherapy are not feasible. The remaining therapeutic options are chemotherapy and endocrine therapy. Areas covered: This review summarizes the development of the first selective estrogen receptor (ER) down-regulator fulvestrant. This article provides its mechanism of action, pharmacokinetics and the available preclinical and clinical data. Furthermore, this review provides an overview of the market of treatments for recurrent or metastatic EC (RMEC) while also taking into account studies of fulvestrant in metastatic breast cancer. Expert opinion: Even if fulvestrant showed only marginal activity in two phase II trials, it shouldn't be abandoned but instead further developed in EC. Firstly, the dose of fulvestrant used in these trials was too low from today's point of view. Secondly, the available literature on other endocrine agents is full of limitations and does not provide a gold standard. Furthermore, given the activity of mTOR inhibitors in EC, there may also be synergistic effects, given the cross-regulation of ER and the PI3K/AKT/mTOR pathway. The authors suggest that a prospective, phase II trial in ER positive RMEC would help to further explore the efficacy and tolerability of fulvestrant together with a mTOR inhibitor.
MeSH term(s)	Animals ; Antineoplastic Agents, Hormonal/adverse effects ; Antineoplastic Agents, Hormonal/chemistry ; Antineoplastic Agents, Hormonal/pharmacology ; Antineoplastic Agents, Hormonal/therapeutic use ; Endometrial Neoplasms/drug therapy ; Endometrial Neoplasms/metabolism ; Estradiol/adverse effects ; Estradiol/analogs & derivatives ; Estradiol/chemistry ; Estradiol/pharmacology ; Estradiol/therapeutic use ; Female ; Humans
Chemical Substances	Antineoplastic Agents, Hormonal ; fulvestrant (22X328QOC4) ; Estradiol (4TI98Z838E)
Language	English
Publishing date	2016
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	1182884-5
ISSN	1744-7658 ; 0967-8298 ; 1354-3784
ISSN (online)	1744-7658
ISSN	0967-8298 ; 1354-3784
DOI	10.1517/13543784.2016.1154532
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3739: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Efficacy and Safety of Immunotherapy for Cervical Cancer-A Systematic Review of Clinical Trials.

Schmidt, Mona W / Battista, Marco J / Schmidt, Marcus / Garcia, Monique / Siepmann, Timo / Hasenburg, Annette / Anic, Katharina

Cancers

2022 Volume 14, Issue 2

Abstract: Purpose: To systematically review the current body of evidence on the efficacy and safety of immunotherapy for cervical cancer (CC).: Material and methods: Medline, the Cochrane Central Register of Controlled Trials and Web of Science were searched ... ...

Abstract	Purpose: To systematically review the current body of evidence on the efficacy and safety of immunotherapy for cervical cancer (CC). Material and methods: Medline, the Cochrane Central Register of Controlled Trials and Web of Science were searched for prospective trials assessing immunotherapy in CC patients in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Full-text articles in English and German reporting outcomes of survival, response rates or safety were eligible. Results: Of 4655 screened studies, 51 were included (immune checkpoint inhibitors (ICI) Conclusion: Strong evidence on the efficacy of strategies to treat recurrent or metastatic cervical cancer is currently limited to pembrolizumab in combination with chemotherapy and bevacizumab, which substantiates an urgent need for large confirmatory trials on alternative immunotherapies. Overall, there is sound evidence on the safety of immunotherapy in CC.
Language	English
Publishing date	2022-01-17
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers14020441
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Prognostic Impact of CD38- and IgκC-Positive Tumor-Infiltrating Plasma Cells in Triple-Negative Breast Cancer.

Heimes, Anne-Sophie / Riedel, Natali / Almstedt, Katrin / Krajnak, Slavomir / Schwab, Roxana / Stewen, Kathrin / Lebrecht, Antje / Battista, Marco Johannes / Brenner, Walburgis / Hasenburg, Annette / Schmidt, Marcus

International journal of molecular sciences

2023 Volume 24, Issue 20

Abstract: Due to a higher mutational load, triple-negative breast cancer (TNBC) is characterized by a higher immunogenicity compared to other subtypes. In this context, we analyzed the prognostic significance of tumor-infiltrating plasma cells in a cohort of 107 ... ...

Abstract	Due to a higher mutational load, triple-negative breast cancer (TNBC) is characterized by a higher immunogenicity compared to other subtypes. In this context, we analyzed the prognostic significance of tumor-infiltrating plasma cells in a cohort of 107 triple-negative breast cancer patients. Tumor-infiltrating plasma cells were analyzed via immunohistochemistry using the plasma cell markers CD38 and IgκC. The prognostic impact of the CD38 and IgκC expression was evaluated using the Kaplan-Meier plots and Cox regression analyses. A Spearman-Rho correlation coefficient was used to evaluate a possible association between plasma cell infiltration and the
MeSH term(s)	Humans ; Biomarkers, Tumor/metabolism ; Disease-Free Survival ; Lymphocytes, Tumor-Infiltrating/metabolism ; Plasma Cells/metabolism ; Prognosis ; Triple Negative Breast Neoplasms/pathology
Chemical Substances	Biomarkers, Tumor ; CD38 protein, human (EC 3.2.2.5) ; IgK
Language	English
Publishing date	2023-10-16
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms242015219
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito